Discover trends, market shifts, and competitive outlooks for the leqvio global market report 2025 industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What is the Projected CAGR for the Leqvio Market Size from 2025 to 2034?

In recent times, the leqvio market has seen an XX (HCAGR). It is forecasted to expand from $XX million in 2024 to $XX million in 2025, exhibiting a compound annual growth rate (CAGR) of XX%. This development throughout the historic period is linked to an upsurge in financing for RNA-based drug development, heightened expenditure on medications for cholesterol management, an increase in R&D investment and medication development, improved healthcare awareness, and a growing demand for specialized medicines.

In the coming years, the market size for leqvio is projected to observe an FCAGR of XX. By 2029, it is anticipated to expand to a market worth of $XX million, with a compound annual growth rate (CAGR) of XX%. The interested period’s expansion is linked to the escalating global rate of cardiovascular diseases, enhanced cognizance of the potency of PCSK9 inhibitors, rise in high cholesterol incidents, increase in the elderly population, and biologic drugs’ evolution. The forecasted era will witness major trends like growing preference for advanced hypercholesterolemia treatments, broadened indications via continuous research, successive approvals from regulatory platforms such as FDA, breakthroughs in biopharmaceutical studies, and drug development advancements.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20143&type=smp

What Are the Core Market Drivers Propelling Growth in the Leqvio Industry?

The anticipated expansion of the leqvio market is largely due to the growing instances of cardiovascular diseases. These diseases – affecting the heart and blood vessels – often lead to severe consequences such as heart attacks, strokes, and hypertension. The rise in these conditions is generally attributed to unhealthy eating habits, lack of physical activity, overconsumption of alcohol, diabetes, and advancing age. Leqvio, works by inhibiting the PCSK9 protein, which bolsters the liver’s function in eliminating LDL cholesterol from our bloodstream. This process essentially reduces LDL levels, lessening the likelihood of heart attacks, strokes, and other related cardiovascular incidents. To exemplify, data published by the British Heart Foundation in September 2024, a cardiovascular research non-profit based in the UK, stated that around 7.6 million individuals in the UK suffer from heart and circulatory diseases. Among these, approximately 4 million are male and 3.6 million are female. Such diseases account for nearly 27% of all deaths in the UK, leading to more than 170,000 fatalities per annum or about 480 per day, translating to one death every three minutes. As such, the mounting cases of cardiovascular diseases are fueling the growth of the Leqvio market.

How Is the Leqvio Market Segmented?

The leqvio market covered in this report is segmented –

1) By Formulation: Injectable Formulation (Subcutaneous), Pre-Filled Syringes Or Auto-Injectors

2) By Indication: Treatment Of Hyperlipidemia, Management Of Atherosclerotic Cardiovascular Disease (ASCVD), Treatment Of Familial Hypercholesterolemia

3) By Patient Demographics: Adult Patients, Geriatric Patients, Patients with Comorbid Conditions

4) By Distribution Channel: Direct Sales, Wholesalers and Distributors, Retail Pharmacies, Online Pharmacies

5) By End-User: Hospitals, Cardiovascular Clinics, Specialty Pharmacies, Home Healthcare Providers

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20143&type=smp

Which Regions Are Driving the Next Phase of the Leqvio Market Growth?

North America was the largest region in the leqvio market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leqvio market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Key Market Trends and Innovations Are Shaping the Future of the Leqvio Industry?

The primary trend in the Leqvio market revolves around the innovation and progression of advanced injectable prescription medication. This aims at providing long-term treatments, bolstering patient compliance and improving results. These injectable prescription medications are administered through injections, primarily intended for managing high cholesterol levels and minimizing cardiovascular threats. Therapy is generally offered at consistent intervals to maintain an enduring therapeutic influence. An example of this was in July 2023 when Novartis, a Swiss firm specializing in pharmaceuticals, gained approval for a label update for Leqvio (inclisiran) from the US FDA. This approval allowed the early use of the medicine in patients with high LDL-C and a heightened risk of cardiac disease, supplementing diet and statin therapy. Administered as two initial doses, followed by two doses annually, Leqvio is documented to reduce LDL-C levels by 52% and is shown to be effective for patients who fail to achieve their LDL-C objectives despite statin therapy. The label update underscores the comprehensive safety and efficacy data, as reinforced through the VictORION clinical trial program.

View the full report here:

https://www.thebusinessresearchcompany.com/report/leqvio-global-market-report

How Is the Leqvio Market Defined and What Are Its Core Parameters?

Leqvio is an siRNA-based therapy that reduces low-density lipoprotein (LDL) cholesterol by silencing the mRNA responsible for PCSK9 production in the liver. It improves the liver’s ability to clear LDL-C from the bloodstream, lowering the risk of heart attacks, strokes, and other cardiovascular events in high-risk patients.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20143

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model